WO2006097629A1 - Composition alimentaire suppletive - Google Patents
Composition alimentaire suppletive Download PDFInfo
- Publication number
- WO2006097629A1 WO2006097629A1 PCT/FR2006/000576 FR2006000576W WO2006097629A1 WO 2006097629 A1 WO2006097629 A1 WO 2006097629A1 FR 2006000576 W FR2006000576 W FR 2006000576W WO 2006097629 A1 WO2006097629 A1 WO 2006097629A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- mmol
- composition according
- potassium
- calcium
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 82
- 235000013305 food Nutrition 0.000 title claims abstract description 10
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 38
- 239000011707 mineral Substances 0.000 claims abstract description 38
- 208000010444 Acidosis Diseases 0.000 claims abstract description 18
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- 206010027417 Metabolic acidosis Diseases 0.000 claims abstract description 17
- 230000002485 urinary effect Effects 0.000 claims abstract description 17
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 15
- 206010020772 Hypertension Diseases 0.000 claims abstract description 13
- 208000015924 Lithiasis Diseases 0.000 claims abstract description 11
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 9
- 230000032683 aging Effects 0.000 claims abstract description 8
- 230000003139 buffering effect Effects 0.000 claims abstract description 6
- -1 hydrogen ions Chemical class 0.000 claims abstract description 6
- 208000006011 Stroke Diseases 0.000 claims abstract description 5
- 239000001257 hydrogen Substances 0.000 claims abstract description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 5
- 239000011575 calcium Substances 0.000 claims description 49
- 229910052791 calcium Inorganic materials 0.000 claims description 47
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 44
- 239000011777 magnesium Substances 0.000 claims description 42
- 229910052749 magnesium Inorganic materials 0.000 claims description 41
- 229910052700 potassium Inorganic materials 0.000 claims description 41
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 40
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 40
- 239000011591 potassium Substances 0.000 claims description 40
- 239000000843 powder Substances 0.000 claims description 24
- 235000005911 diet Nutrition 0.000 claims description 16
- 230000037213 diet Effects 0.000 claims description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 10
- 235000013399 edible fruits Nutrition 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 235000013406 prebiotics Nutrition 0.000 claims description 7
- 159000000007 calcium salts Chemical class 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 230000002378 acidificating effect Effects 0.000 claims description 5
- 150000001860 citric acid derivatives Chemical class 0.000 claims description 5
- 229940100688 oral solution Drugs 0.000 claims description 4
- 235000003599 food sweetener Nutrition 0.000 claims description 3
- 159000000003 magnesium salts Chemical class 0.000 claims description 3
- 229940049920 malate Drugs 0.000 claims description 3
- 239000003765 sweetening agent Substances 0.000 claims description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
- 239000002535 acidifier Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000010790 dilution Methods 0.000 claims description 2
- 239000012895 dilution Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 159000000001 potassium salts Chemical class 0.000 claims description 2
- 210000002249 digestive system Anatomy 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000019634 flavors Nutrition 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 239000002253 acid Substances 0.000 abstract description 9
- 230000001079 digestive effect Effects 0.000 abstract description 3
- 229940091250 magnesium supplement Drugs 0.000 description 38
- 229960003975 potassium Drugs 0.000 description 38
- 239000011734 sodium Substances 0.000 description 33
- 235000010755 mineral Nutrition 0.000 description 31
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 28
- 229910052708 sodium Inorganic materials 0.000 description 28
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- 230000003834 intracellular effect Effects 0.000 description 21
- 230000000694 effects Effects 0.000 description 20
- 230000007423 decrease Effects 0.000 description 11
- 230000029142 excretion Effects 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 10
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 9
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 8
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 8
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 208000019025 Hypokalemia Diseases 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 206010022489 Insulin Resistance Diseases 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 238000001125 extrusion Methods 0.000 description 6
- 208000008167 Magnesium Deficiency Diseases 0.000 description 5
- 229930003316 Vitamin D Natural products 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 235000004764 magnesium deficiency Nutrition 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000001508 potassium citrate Substances 0.000 description 5
- 208000007645 potassium deficiency Diseases 0.000 description 5
- 230000036325 urinary excretion Effects 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 235000019166 vitamin D Nutrition 0.000 description 5
- 239000011710 vitamin D Substances 0.000 description 5
- 150000003710 vitamin D derivatives Chemical class 0.000 description 5
- 229940046008 vitamin d Drugs 0.000 description 5
- 244000298479 Cichorium intybus Species 0.000 description 4
- 235000007542 Cichorium intybus Nutrition 0.000 description 4
- 235000005979 Citrus limon Nutrition 0.000 description 4
- 244000131522 Citrus pyriformis Species 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 4
- 239000001354 calcium citrate Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000001631 hypertensive effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- 235000005282 vitamin D3 Nutrition 0.000 description 4
- 239000011647 vitamin D3 Substances 0.000 description 4
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 4
- 229940021056 vitamin d3 Drugs 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 230000009102 absorption Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 229960005069 calcium Drugs 0.000 description 3
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 230000024924 glomerular filtration Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000004941 influx Effects 0.000 description 3
- 230000031891 intestinal absorption Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000003891 oxalate salts Chemical class 0.000 description 3
- 235000011082 potassium citrates Nutrition 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 235000013337 tricalcium citrate Nutrition 0.000 description 3
- 235000015870 tripotassium citrate Nutrition 0.000 description 3
- 208000008281 urolithiasis Diseases 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 229940121819 ATPase inhibitor Drugs 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010020590 Hypercalciuria Diseases 0.000 description 2
- 206010021027 Hypomagnesaemia Diseases 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- 208000000913 Kidney Calculi Diseases 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 102000008934 Muscle Proteins Human genes 0.000 description 2
- 108010074084 Muscle Proteins Proteins 0.000 description 2
- 206010029148 Nephrolithiasis Diseases 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010041277 Sodium retention Diseases 0.000 description 2
- 102000005393 Sodium-Potassium-Exchanging ATPase Human genes 0.000 description 2
- 108010006431 Sodium-Potassium-Exchanging ATPase Proteins 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 235000021120 animal protein Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000029215 cell volume homeostasis Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 229960002061 ergocalciferol Drugs 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000037041 intracellular level Effects 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 230000019948 ion homeostasis Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 235000002538 magnesium citrate Nutrition 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004118 muscle contraction Effects 0.000 description 2
- 230000001582 osteoblastic effect Effects 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- 208000024896 potassium deficiency disease Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- 235000001892 vitamin D2 Nutrition 0.000 description 2
- 239000011653 vitamin D2 Substances 0.000 description 2
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 241000234282 Allium Species 0.000 description 1
- 235000005254 Allium ampeloprasum Nutrition 0.000 description 1
- 240000006108 Allium ampeloprasum Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 244000003416 Asparagus officinalis Species 0.000 description 1
- 235000005340 Asparagus officinalis Nutrition 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 102000005702 Calcium-Activated Potassium Channels Human genes 0.000 description 1
- 108010045489 Calcium-Activated Potassium Channels Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 244000019459 Cynara cardunculus Species 0.000 description 1
- 235000019106 Cynara scolymus Nutrition 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 244000288157 Passiflora edulis Species 0.000 description 1
- 235000000370 Passiflora edulis Nutrition 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 244000171263 Ribes grossularia Species 0.000 description 1
- 235000002357 Ribes grossularia Nutrition 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 102000001794 Sodium-Calcium Exchanger Human genes 0.000 description 1
- 108010040240 Sodium-Calcium Exchanger Proteins 0.000 description 1
- 101000640897 Squalus acanthias Solute carrier family 12 member 2 Proteins 0.000 description 1
- 244000294925 Tragopogon dubius Species 0.000 description 1
- 235000004478 Tragopogon dubius Nutrition 0.000 description 1
- 235000012363 Tragopogon porrifolius Nutrition 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 230000003113 alkalizing effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000002337 anti-port Effects 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000016520 artichoke thistle Nutrition 0.000 description 1
- FYGDTMLNYKFZSV-XJJKTWKOSA-N beta-(1->4)-galactotriose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H](CO)O[C@@H](O[C@H]2[C@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-XJJKTWKOSA-N 0.000 description 1
- 230000001847 bifidogenic effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 230000037176 bone building Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 235000011001 calcium citrates Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000037020 contractile activity Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000003911 electrolyte status Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000007951 extracellular acidosis Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- DBTMGCOVALSLOR-AXAHEAMVSA-N galactotriose Natural products OC[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](CO)O[C@@H](O[C@H]3[C@@H](O)[C@H](O)O[C@@H](CO)[C@@H]3O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O DBTMGCOVALSLOR-AXAHEAMVSA-N 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 230000000910 hyperinsulinemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Substances N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000000210 loop of henle Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000004337 magnesium citrate Substances 0.000 description 1
- 229960005336 magnesium citrate Drugs 0.000 description 1
- UHNWOJJPXCYKCG-UHFFFAOYSA-L magnesium oxalate Chemical compound [Mg+2].[O-]C(=O)C([O-])=O UHNWOJJPXCYKCG-UHFFFAOYSA-L 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 150000004701 malic acid derivatives Chemical class 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000012241 membrane hyperpolarization Effects 0.000 description 1
- 235000020802 micronutrient deficiency Nutrition 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000020988 regulation of intracellular pH Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008060 renal absorption Effects 0.000 description 1
- 208000001076 sarcopenia Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000010245 tubular reabsorption Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/22—Comminuted fibrous parts of plants, e.g. bagasse or pulp
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/40—Table salts; Dietetic salt substitutes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a suppletive food composition intended to be administered orally as a dietary supplement.
- This composition aims to improve the prevention of ionic and mineral disorders observed for example during aging, high protein and restrictive diets, low in minerals and in various pathologies such as metabolic acidosis, hypertension, cardiovascular diseases, type 2 diabetes, lithiasis,
- the contemporary diet can be at the origin of acid-base and mineral imbalances, as well as disorders of the ionic homeostasis which will lead to disturbances of the physiological functions even to potentiate various pathologies such as the hypertension, the cardiovascular diseases, 1 Osteoporosis, lithiasis and type 2 diabetes.
- NAE Acid renal excretion
- HTA hypertension
- type 2 diabetes In pathologies such as hypertension (HTA) and type 2 diabetes, elevation of free cytosolic calcium is observed while extracellular concentrations of ionized calcium are reduced. Such modifications are also encountered in the elderly. As a result, high cytosolic basal contents of free calcium and an alteration of calcium transport at the membrane level are found in the platelets, erythrocytes, lymphocytes and adipocytes of hypertensive subjects. Blood pressure correlates directly with intracellular calcium levels.
- Type 2 diabetes In type 2 diabetes, even in the absence of hypertension, intracellular calcium levels are also high. Calcium transport defects are found in all tissues in type 2 diabetics, including cardiac and skeletal muscles, arteries, kidney, liver, erythrocytes, osteoblasts, adipocytes and platelets.
- Intracellular potassium is decreased in treated and non-hypertensive individuals, as well as in type 2 diabetics. In non-diabetic subjects, however, an inverse correlation was found between intracellular potassium and blood pressure level.
- the ATP-dependent sodium / potassium pump (NaK-ATPase) is the main mechanism responsible for maintaining the low intracellular sodium concentration and the high intracellular potassium concentration.
- the pump is the main mechanism responsible for maintaining the low intracellular sodium concentration and the high intracellular potassium concentration.
- NaK-ATPase is responsible for maintaining the membrane potential.
- the activity and capacity of NaK-ATPase is under the control of hormones, contractile activity, exercise, nutrition and electrolyte status.
- potassium deficiency leads to a reduction in the concentration of NaK-ATPase in skeletal muscle.
- the potassium deficiency induced by diuretic treatments induces the same effects.
- a 53% reduction in muscle NaK-ATPase concentration results in a 88% reduction in the strength rate.
- NHE sodium / proton exchanger
- Sodium cotransport / potassium / 2 chlorides (Na + / K + / 2C1 ⁇ ) (NKCC) plays an important role in maintaining the chlorine (Cl ”) intracellular.
- High concentrations of Cl" inhibit ion flow in both directions .
- this transporter could be important in the regulation of cell volume.
- the NaVMg 2+ exchanger is responsible in part for the extrusion of magnesium out of the cell. Although this antiport is not the main regulator of intracellular magnesium concentrations, it allows magnesium efflux proportionally to the extracellular sodium content.
- NaCl loading is accompanied by increased cellular concentrations of sodium and calcium, but decreased magnesium levels.
- a magnesium charge lowers intracellular sodium and increases intracellular magnesium levels.
- the decrease in intracellular sodium is accompanied by a drop in blood pressure.
- Supplementation with potassium and magnesium prevents the induction of NaK-ATPase inhibition. The effects of potassium and magnesium seem additive.
- Potassium deficiency including both hypokalemia and decreased intracellular potassium may be a consequence of magnesium deficiency.
- This magnesocurable and non-kaliocurable potassium depletion is related to membrane modifications and in particular to an inhibition of the magnesium-dependent NaK-ATPase activity, which is essential for the transport of potassium and sodium into the interior and exterior of the cell. cell.
- Magnesium also blocks the potassium currents exiting at the level of the potassium channels.
- magnesium is essential for the reabsorption of potassium in the loop of Henle and the magnesium deficit stimulates the secretion of renin and aldosterone, resulting in a kaliuria. Potassium deficiency contributes to the cardiovascular consequences of magnesium deficiency.
- sodium plays an important role in the activation of NaK-ATPase. Indeed, the sodium dietary sodium chloride provides induction of an inhibitor of NaK-ATPase activity, which contributes to the accumulation of sodium in the cell. On the other hand, if the sodium is introduced in a form other than chloride, it does not induce the synthesis of the NaK-ATPase inhibitor. Finally, NaCl facilitates the activity of the NaVH + exchanger. Conversely, potassium decreases the activity of this sodium-proton exchanger. In addition, potassium and magnesium inhibit synthesis of the NaK-ATPase inhibitor. Therefore, it appears that sodium chloride facilitates the cell's retention of sodium, while dietary potassium and magnesium facilitate the extrusion of sodium from the cell.
- the cellular mechanisms described above and involved in ionic transport could be observed at the level of different organs such as, for example, the heart and the kidney.
- sodium it seems confirmed that it is the combination of sodium and chlorine that has deleterious effects.
- the increase in vascular volume observed during a sodium chloride loading could be explained by the induction of an inhibitor of the NaK-ATPase pump.
- the effect of NaCl on vascular volume expansion is thought to be related to the role of Na / K / 2C1 cotransport in sodium retention at the renal level. This mechanism would be inoperative at low concentrations of chlorine in the tubular fluid.
- calcium it plays an important role at the cellular level. He intervenes in particular in the processes of muscular contraction, described in the problems of HTA. In spontaneously hypertensive rat SHR, a calcium-rich diet increases urinary sodium excretion, erythrocyte membrane Ca-ATPase activity reduces intracellular calcium concentration in platelets, and improves muscle cell relaxation. vascular smooth. This calcium effect appears to be related to an improvement in membrane hyperpolarization by opening calcium-activated potassium channels.
- the magnesium deficiency promotes dyslipidemia, increases the peroxidation of lipoproteins and induces an inflammatory response.
- lithiasis has increased steadily in recent decades. This is largely related to changes in eating habits: consumption of animal protein, NaCl, alcohol, intake of insufficient drink are all dietary factors aggravating the risk of urinary stones. Excessive intake of animal protein leads to a lowering of urine pH, while excretion of calcium, oxalate and uric acid is increased. Lithiases are also associated with acidification of the urine, linked in particular to the reduction of the excretion of citrates. In addition, urinary lithiasis is associated with significant mineral losses. Indeed, a high urinary sodium excretion is usually observed in people with stones.
- Potassium depletion leads to changes in the expression of NaK-ATPase in skeletal muscle, heart and nerves, which may also play an important role in the pathophysiology of diabetes.
- the ionic hypothesis could explain the concomitant appearance of several pathologies during the polymetabolic syndrome. This is corroborated by the fact that insulin resistance and hyperinsulinemia are both associated with mineral imbalances.
- the effect of potassium deficiency in the genesis of type 2 diabetes may also be related to a disturbance of magnesium homeostasis.
- low plasma concentrations of potassium could interfere with renal reabsorption of magnesium and therefore lead to hypomagnesemia.
- PTH parathyroid hormone
- the effectiveness of calcium absorption decreases with age, frequently associated with inadequate dietary intake, vitamin D deficiency, and compensatory hyperparathyroidism. Aging is usually accompanied by renal changes including a decrease in glomerular filtration. The glomerular filtration rate decreases by about 1.05 ml / min per year in the elderly.
- Age and glomerular filtration are two non-dissociable factors responsible for the control of blood acidity and plasma bicarbonates.
- Metabolic acidosis promotes muscle protein catabolism.
- osteoporosis is characterized not only by a loss of bone calcium stock but also by an alteration of the protein matrix of the bone. It is easy to imagine that this type of synergy that can be established in case of prolonged metabolic acidosis can have very deleterious effects.
- Sarcopenia is certainly a multifactorial phenomenon: slow erosion of muscle proteins, dysregulation of cytokines, degeneration of motor neurons, physical inactivity, decreased levels of hormones. But, another hypothesis is also advanced, in relation to the effects of metabolic acidosis. Indeed, the decline of renal function associated with an acidifying diet, in the elderly, could contribute to accentuate protein catabolism in these people.
- fructo-oligosaccharides helps to maintain intestinal flora.
- the FOS prevent the appearance of diarrhea which can be at the origin of digestive losses mineral (Ca, Mg, K %) and ionic (bicarbonates ).
- the FOS facilitate the intestinal absorption of certain minerals.
- stimulation of the absorption of minerals such as Ca 2+ and Mg 2+ by inulin has been repeatedly confirmed in the rat. It appears that the use of different models (rats and hamsters) indicates an increase in absorption in the large intestine to result in an increase in bone density.
- Kidney stones are the result of a complex between calcium and oxalate.
- An acidic charge is usually accompanied by an excess of oxalic acid contributing to the formation of these calcium crystals.
- Citrate plays an important role in the metabolism of calcium, and in particular in the inhibition of the formation of these calcium crystals.
- urinary citrate is an endogenous inhibitor of crystal formation by complexing with calcium.
- Low urinary citrate levels are associated with the development of kidney stones.
- the alkalizing drinks prevent the formation of calcium oxalate, uric acid and lithiasis.
- citric acid-rich fruit powders increase urinary pH and urinary excretion of citrate, reducing the risk of crystallization between calcium and oxalic acid.
- citrate salts reduce the degree of metabolic acidosis, thereby limiting urinary mineral and ionic losses, while improving the bicarbonate status of the body. They help to reduce the NAE.
- Potassium plays a key role in maintaining ionic homeostasis at the cellular level. Indeed, potassium prevents the induction of the inhibitor of NaK-ATPase, and therefore contributes to the maintenance of the membrane potential. In addition, it reduces the risk of stroke.
- potassium intervenes at the urinary level by facilitating the excretion of citrate, thus preventing the formation of calcium crystals and thus lithiasis.
- Calcium also prevents the development of lithiasis by preventing intestinal absorption of oxalates. Calcium also decreases the risk of developing diabetes.
- calcium is essential in bone building. It is incorporated in the mineral fraction of the bone.
- Adequate calcium intake appears to be essential for maintaining the skeleton, especially during metabolic acidosis induced by food.
- Magnesium plays a role similar to that of potassium. Their effects are additive at the cellular level, in particular by their effect on NaK-ATPase. In fact, magnesium also prevents the induction of the inhibitor of this pump. In addition, at the cellular level, magnesium blocks outgoing potassium currents and facilitates the extrusion of sodium out of the cell.
- Magnesium also acts as a cofactor for many enzymes. Its involvement in the functioning of NaK-ATPase makes it an important mineral in the maintenance of mineral balances at the cellular level.
- magnesium has a number of effects on citrate metabolism and reduces saturation urinary calcium oxalate forming magnesium oxalate, more soluble than calcium oxalate.
- magnesium can also form complexes with oxalates, thus reducing the intestinal absorption of oxalates.
- the aim of the invention is to provide a food composition that enables micronutritional management with a view to preventing the occurrence of disorders related to mineral and ionic imbalances, as well as to increased mineral and ionic urinary excretions, such as metabolic acidosis. , hypertension, stroke, type 2 diabetes, osteoporosis, urinary lithiasis.
- the present invention firstly relates to a composition, preferably a suppletive food composition, comprising at least one inorganic organic salt, which inorganic organic salt contributes to the alkaline power in an amount ranging from 20 to 200 mEq, capable of buffering a acid charge of 20 to 200 mEq of hydrogen ions H + , ie 20 to 200 mmol of H + , preferably 40 to 100 mEq.
- the inventors have found that the compounds used in the composition according to the invention have complementary modes of action, thus offering a synergy for a more effective action, and that the mixture of these in specific quantities makes it possible to obtain a composition in powder form dissolving without difficulty.
- the inorganic organic salt may be selected from potassium salts, magnesium salts or calcium salts.
- composition according to the invention may comprise only one of these salts or any combination thereof.
- the inorganic organic salt is a mixture of potassium, magnesium and calcium salts.
- the inorganic organic salt may be chosen from citrate, malate, lactate or gluconate salts, preferably citrate salts.
- the composition according to the invention may comprise only one of these salts or any combination thereof.
- the inorganic organic salt may be chosen from potassium, magnesium or calcium citrates, most preferably potassium citrate and, particularly preferably, the inorganic organic salt is a mixture of potassium citrates, magnesium and calcium.
- the potassium When a potassium salt is used, the potassium may be present in the composition according to the invention in an amount ranging from 2 mmol to 75 mmol, preferably from 10 mmol to 50 mmol. According to one particular form of the invention, the potassium may be present in the composition in the form of tri-potassium citrate.
- the calcium When a calcium salt is used, the calcium may be present in the composition according to the invention in an amount ranging from 1 mmol to 30 mmol, preferably from 5 mmol to 20 mmol. According to one particular form of the invention, the calcium may be present in the composition in the form of tri-calcium citrate.
- the magnesium may be present in the composition according to the invention in an amount ranging from 1 mmol to 20 mmol, preferentially from 4 mmol to 12 mmol. According to one particular form of the invention, the magnesium may be present in the composition in the form of tri-magnesium citrate.
- compositions according to the invention may be in the form of a powder for dilution, an oral solution, a powder for capsule, a tablet or even granules.
- the composition according to the invention is in the form of powder to be diluted.
- the composition according to is in the form of an oral solution.
- said solution comprises a volume of
- 100 ml to 2 1 when the latter is intended for daily administration preferably from 200 to 1000 ml and particularly preferably from 300 to 800 ml, in particular 500 ml.
- the composition according to the invention further comprises a prebiotic.
- said prebiotic may be chosen from fructo-oligosaccharides of inulin or oligo-fructose type, galactooligosaccharides of transgalacto-oligosaccharide or galactotriose type, isomalto-oligosaccharides or even manno-oligosaccharides.
- the prebiotic may be chosen from fructo-oligosaccharides. Even more preferably, the prebiotic may be chosen from oligofructose fructo-oligosaccharides.
- the oligofructoses can be derived from chicory, onion, garlic, artichoke, leeks, salsify, asparagus, preferably chicory.
- the prebiotic may be present in the composition according to the invention in an amount ranging from 2 g to 15 g, preferably from 2 g to 6 g.
- composition according to the invention further comprises fruit powder.
- the fruit powder can be rich in organic salts, such as citrate salts and / or malate salts.
- the salts may be mineral citrate and / or mineral malate where the minerals may be potassium, calcium, magnesium, zinc, manganese, preferably potassium, calcium, magnesium, and most preferably potassium .
- said fruit powder may be chosen from lemon powder, orange powder, passion fruit powder, pomelo powder, red fruit powder such as gooseberry, blueberry or raspberry, or plum powder.
- the fruit powder is lemon powder.
- the fruit powder can contribute to the alkaline power in an amount ranging from 5 mEq to 30 mEq, capable of buffering an acidic charge of 5 to 30 mEq of H + hydrogen ions, ie 5 to 30 mmol of H + .
- composition of the invention may further comprise vitamin D and / or glutamine.
- Vitamin D may be present in the composition according to the invention in the form of cholecalciferol (vitamin D3), or ergocalciferol (vitamin D2).
- vitamin D is present in the composition in the form of cholecalciferol (vitamin D3).
- Vitamin D may be present in the composition according to the invention in an amount ranging from 1 ⁇ g to 20 ⁇ g, preferably from 2.5 ⁇ g to 15 ⁇ g.
- Glutamine may be present in the composition according to the invention in the form of free L-glutamine or proteins or protein extracts rich in glutamine.
- glutamine is present in the composition in the form of free L-glutamine.
- Glutamine may be present in the composition according to the invention in an amount ranging from 100 mg to 10 g, preferably from 100 mg to 3 g. Those skilled in the art can adapt the amount of protein or protein extract containing glutamine to obtain the desired amount of glutamine in the composition according to the invention.
- composition may further comprise any other
- Active ingredient known for the treatment of disorders related to ionic and mineral imbalances especially those known in diuretic treatments, antihypertensive treatments, treatments for type 2 diabetes, osteoporosis treatments, lithiasis treatments .
- compositions according to the invention may also, according to the formulation chosen, comprise any suitable excipient, such as an acidifier, an anti-caking agent, a dye, an aroma or a sweetener.
- suitable excipient such as an acidifier, an anti-caking agent, a dye, an aroma or a sweetener.
- a preferred composition according to the invention comprises:
- composition may also comprise:
- compositions intended for a half-day administration will comprise the various components described above in an amount corresponding to half of the quantities described above.
- auxiliary composition according to the invention for the preparation of a composition intended to prevent the occurrence of disorders related to ionic and mineral imbalances.
- the subject of the invention is the use of the composition according to the invention for the preparation of a composition intended to prevent and / or compensate mineral and ionic losses by urinary and / or digestive route, to prevent and / or to improve the ionic and mineral imbalances observed in metabolic acidosis, hypertension, stroke, type 2 diabetes, lithiasis, osteoporosis, aging and acidifying diets such as high protein and restrictive diets, low in minerals.
- said composition according to the invention relates to the preparation of a composition intended to prevent and / or compensate for mineral and ionic losses through the urine.
- the subject of the invention is the use of the composition according to the invention for the preparation of a composition rich in minerals for overcoming micronutrient deficiency.
- Tripotassium citrate 2.78 g (ie 1000 mg or 25.6 mmol of potassium)
- Tricalcium citrate 1.9g (ie 400 mg or 10 mmol of calcium)
- Magnesium citrate 1.43g (ie 150 mg or 6.25 mmol of magnesium)
- the different ingredients used correspond to an alkaline intake of about 65 mEg.
- An urinary acid net excretion (NAE) assay was performed before and after said consumption according to the protocol written in the ENA-test kit designed by ABP.
- the assay is performed on the urine collected during a period of 24 hours.
- NAE obtained correlates with the degree of metabolic acidosis.
- composition according to the invention makes it possible to reduce the degree of metabolic acidosis, and therefore the urinary excretion of minerals.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002601103A CA2601103A1 (fr) | 2005-03-15 | 2006-03-15 | Composition alimentaire suppletive |
EP06743576A EP1858353A1 (fr) | 2005-03-15 | 2006-03-15 | Composition alimentaire suppletive |
US11/886,140 US20080206412A1 (en) | 2005-03-15 | 2006-03-15 | Supplementary Food Compositions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0502552 | 2005-03-15 | ||
FR0502552A FR2883132B1 (fr) | 2005-03-15 | 2005-03-15 | Composition alimentaire suppletive |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006097629A1 true WO2006097629A1 (fr) | 2006-09-21 |
Family
ID=35207427
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2006/000576 WO2006097629A1 (fr) | 2005-03-15 | 2006-03-15 | Composition alimentaire suppletive |
Country Status (5)
Country | Link |
---|---|
US (1) | US20080206412A1 (fr) |
EP (1) | EP1858353A1 (fr) |
CA (1) | CA2601103A1 (fr) |
FR (1) | FR2883132B1 (fr) |
WO (1) | WO2006097629A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080193525A1 (en) * | 2007-02-09 | 2008-08-14 | Board Of Regents, The University Of Texas System | Potassium-magnesium citrate as a surrogate of the dash diet in managing hypertension |
EP2080437A1 (fr) * | 2007-12-28 | 2009-07-22 | Kraft Foods Global Brands LLC | Fortification au potassium d'aliments |
WO2010081913A3 (fr) * | 2009-01-19 | 2011-05-12 | Université De Liège Gembloux Agro-Bio Tech | Procédé de production d'une composition, composition et utilisation de cette composition comme additif alimentaire |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2010000660A (es) * | 2009-12-11 | 2011-06-14 | Abbott Lab | Soluciones de rehidratacion oral que comprenden dextrosa. |
DE102011000997A1 (de) * | 2011-03-01 | 2012-09-06 | Gelita Ag | Zusammensetzung für Ernährungszwecke |
BE1020304A5 (fr) * | 2011-12-06 | 2013-07-02 | Manfred Jacob Ludwig | Une composition contenant du citrate de potassium, de calcium, de magnesium et de la vitamine d. |
IL247130B (en) * | 2015-08-06 | 2021-06-30 | Kenneth Davin Fine | A compound for blocking and absorbing oxalate for use in the treatment of pain due to fibromyalgia, calcification of the spinal cord and calcification of the shoulder |
EP3135273B1 (fr) * | 2015-08-25 | 2020-07-15 | Protina Pharmazeutische Gesellschaft mbH | Compositions de matieres minerales destinees a amorcer le metabolisme glucidique |
WO2019201707A1 (fr) * | 2018-04-19 | 2019-10-24 | Prosalix Ag | Mélange de substances comprenant du citrate de k-mg pour utilisation comme médicament |
DE102019128196A1 (de) | 2019-10-18 | 2021-04-22 | Prosalix Ag | Präparat zur medizinischen Verwendung für die Behandlung einer Krankheit infolge Schädigung der tubulären Nierenfunktion |
CN114794346A (zh) * | 2022-04-25 | 2022-07-29 | 武汉汇天诚科技有限公司 | 一种复合固体饮料的配方 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09191852A (ja) * | 1996-01-19 | 1997-07-29 | Sennosuke Tokumaru | 健康食品 |
CN1163073A (zh) * | 1996-04-24 | 1997-10-29 | 厦门大学 | 固体发泡饮料及其制造方法 |
WO1998053708A1 (fr) * | 1997-05-30 | 1998-12-03 | Campbell Soup Company | Compositions salines renforçant l'arome |
WO2000040705A2 (fr) * | 1999-01-08 | 2000-07-13 | Abbott Laboratories | Gene desaturase humain et ses utilisations |
WO2000044245A1 (fr) * | 1999-01-27 | 2000-08-03 | Maeki Juhani Ilpo Tapio | Produit sale alimentaire physiologique |
WO2001097633A2 (fr) * | 2000-06-19 | 2001-12-27 | General Mills, Inc. | Groupes d'elements nutritifs pour aliments et leurs procedes de preparation |
WO2003053163A2 (fr) * | 2001-12-17 | 2003-07-03 | Larena | Composition de sel pauvre en chlorure de sodium et riche en sel organique de potassium et ses utilisations |
WO2003053165A1 (fr) * | 2001-12-20 | 2003-07-03 | N.V. Nutricia | Composition contenant de la pectine formant une matrice |
EP1388297A1 (fr) * | 2002-08-06 | 2004-02-11 | Nestec S.A. | Agent pour améliorer l'absorption du calcium |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5851578A (en) * | 1997-02-21 | 1998-12-22 | Soma Technologies | Clear or translucent liquid beverage with souluble fiber and nutrients |
US6866877B2 (en) * | 1998-12-29 | 2005-03-15 | Mac Farms, Inc. | Carbonated fortified milk-based beverage and method for suppressing bacterial growth in the beverage |
US6436446B1 (en) * | 1999-07-30 | 2002-08-20 | Pharmavite Llc | Composition for increasing bone density |
-
2005
- 2005-03-15 FR FR0502552A patent/FR2883132B1/fr not_active Expired - Fee Related
-
2006
- 2006-03-15 WO PCT/FR2006/000576 patent/WO2006097629A1/fr active Application Filing
- 2006-03-15 US US11/886,140 patent/US20080206412A1/en not_active Abandoned
- 2006-03-15 CA CA002601103A patent/CA2601103A1/fr not_active Abandoned
- 2006-03-15 EP EP06743576A patent/EP1858353A1/fr not_active Withdrawn
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09191852A (ja) * | 1996-01-19 | 1997-07-29 | Sennosuke Tokumaru | 健康食品 |
CN1163073A (zh) * | 1996-04-24 | 1997-10-29 | 厦门大学 | 固体发泡饮料及其制造方法 |
WO1998053708A1 (fr) * | 1997-05-30 | 1998-12-03 | Campbell Soup Company | Compositions salines renforçant l'arome |
WO2000040705A2 (fr) * | 1999-01-08 | 2000-07-13 | Abbott Laboratories | Gene desaturase humain et ses utilisations |
WO2000044245A1 (fr) * | 1999-01-27 | 2000-08-03 | Maeki Juhani Ilpo Tapio | Produit sale alimentaire physiologique |
WO2001097633A2 (fr) * | 2000-06-19 | 2001-12-27 | General Mills, Inc. | Groupes d'elements nutritifs pour aliments et leurs procedes de preparation |
WO2003053163A2 (fr) * | 2001-12-17 | 2003-07-03 | Larena | Composition de sel pauvre en chlorure de sodium et riche en sel organique de potassium et ses utilisations |
WO2003053165A1 (fr) * | 2001-12-20 | 2003-07-03 | N.V. Nutricia | Composition contenant de la pectine formant une matrice |
EP1388297A1 (fr) * | 2002-08-06 | 2004-02-11 | Nestec S.A. | Agent pour améliorer l'absorption du calcium |
Non-Patent Citations (2)
Title |
---|
DATABASE WPI Section Ch Week 199740, Derwent World Patents Index; Class B04, AN 1997-429154, XP002353788 * |
DATABASE WPI Section Ch Week 200318, Derwent World Patents Index; Class D13, AN 2003-175826, XP002353789 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080193525A1 (en) * | 2007-02-09 | 2008-08-14 | Board Of Regents, The University Of Texas System | Potassium-magnesium citrate as a surrogate of the dash diet in managing hypertension |
US10251909B2 (en) * | 2007-02-09 | 2019-04-09 | Board Of Regents, The University Of Texas System | Potassium-magnesium citrate as a surrogate of the DASH diet in managing hypertension |
EP2080437A1 (fr) * | 2007-12-28 | 2009-07-22 | Kraft Foods Global Brands LLC | Fortification au potassium d'aliments |
US9017748B2 (en) | 2007-12-28 | 2015-04-28 | Kraft Foods Group Brands Llc | Potassium fortification in foodstuffs |
WO2010081913A3 (fr) * | 2009-01-19 | 2011-05-12 | Université De Liège Gembloux Agro-Bio Tech | Procédé de production d'une composition, composition et utilisation de cette composition comme additif alimentaire |
Also Published As
Publication number | Publication date |
---|---|
FR2883132A1 (fr) | 2006-09-22 |
FR2883132B1 (fr) | 2009-02-13 |
CA2601103A1 (fr) | 2006-09-21 |
EP1858353A1 (fr) | 2007-11-28 |
US20080206412A1 (en) | 2008-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1858353A1 (fr) | Composition alimentaire suppletive | |
EP0969744B1 (fr) | Composition nutritionnelle servant a ameliorer la capacite energetique cellulaire | |
CN100415224C (zh) | 包含脂肪酸和氨基酸的组合物 | |
US20070224292A1 (en) | Extended effect ergogenic drink | |
CA2517172C (fr) | Compositions therapeutiques | |
DE60125191T2 (de) | Zusammensetzungen und methoden zur verbesserung der kardiovaskulären funktion | |
JP2006241140A (ja) | 肝疾患用栄養組成物 | |
US20210353578A1 (en) | Dietary macro/micronutritional supplement for patients undergoing kidney dialysis | |
CN101642468A (zh) | 用于降低血糖和血脂的药物组合物 | |
CN101601681A (zh) | 用于降低血糖和血脂的药物组合物 | |
US9585898B2 (en) | Method for the reduction of dangerous blood sugar levels | |
JP2006022072A (ja) | 食欲コントロール剤 | |
JPS58135812A (ja) | マグネシウム代謝調節剤 | |
Aub | Annual Graduate Fortnight:“Disorders of Metabolism”, October 23 to November 3, 1933: Mineral Metabolism | |
US20210346334A1 (en) | Nutritional chromium compositions and methods of use | |
BE1020304A5 (fr) | Une composition contenant du citrate de potassium, de calcium, de magnesium et de la vitamine d. | |
DE19654822C1 (de) | Mittel zur Prävention defizitbedingter Infektions- und Alterserkrankungen | |
CN101574368A (zh) | 用于降低血糖和血脂的药物组合物 | |
CN101474204A (zh) | 用于降低血脂的药物组合物 | |
DE202006006049U1 (de) | Alkoholfreies Getränk als Lebensmittelzusatz | |
Gervang et al. | Calcium revisited | |
Valim et al. | Orange juice and blood pressure | |
McLaren | Excessive nutrient intakes | |
AT6932U1 (de) | Kombinations-präparat, enthaltend mineralstoffe, vitamine, kohlenhydrate und aminosäuren | |
CN101628024A (zh) | 用于降低血糖的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2601103 Country of ref document: CA Ref document number: 2006743576 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11886140 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2006743576 Country of ref document: EP |